

Seven compounds from Portulaca oleracea L. and their anticholinesterase activities

Wen Xu, Jianhua Wang, Baozhao Ju, Xiujuan Lan, Xixiang Ying, Didier Stien

► To cite this version:

Wen Xu, Jianhua Wang, Baozhao Ju, Xiujuan Lan, Xixiang Ying, et al.. Seven compounds from Portulaca oleracea L. and their anticholinesterase activities. Natural Product Research, 2022, 36, pp.2547-2553. 10.1080/14786419.2021.1916928 . hal-03216986

HAL Id: hal-03216986 https://hal.science/hal-03216986

Submitted on 4 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Seven compounds from Portulaca oleracea L. and their anticholinesterase
2	activities
3	Wen Xu ^{a,†} , Jianhua Wang ^{b,†} , Baozhao Ju ^b , Xiujuan Lan ^a , Xixiang Ying ^{a, *} and
4	Didier Stien ^{c, *}
5	Affiliation
6	^a School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian,
7	China
8	^b School of Traditional Chinese Medicine, Liaoning University of Traditional Chinese
9	Medicine, Shenyang, China
10	^c Sorbonne Université, CNRS, Laboratoire de Biodiversité et Biotechnologie
11	Microbiennes (LBBM), Observatoire Océanologique, Banyuls-sur-Mer, France
12	E-mail address in order:
13	xuwen199654@163.com, wjh-1985@163.com, jubaozhao@163.com,
14	xiujuanlan@139.com, yingxixiang@163.com, and didier.stien@cnrs.fr
15	*Correspondence
16	Correspondence author: Prof. Xixiang Ying, School of Pharmacy, Liaoning
17	University of Traditional Chinese Medicine, No.77, Shengming 1 Road, DD Port,
18	Dalian, 116600, P.R. China, Tel: +86-0411-85890139, Fax: +86-0411-85890128,
19	yingxixiang@163.com
20	Correspondence author: Dr. Didier Stien, Sorbonne Université, CNRS, Laboratoire
21	de Biodiversité et Biotechnologie Microbiennes, LBBM, Observatoire
22	Océanologique, 66650 Banyuls-sur-Mer, France, Tel: +33-430192476,
23	didier.stien@cnrs.fr
24	[†] Wen Xu and Jianhua Wang contributed equally to this work.

Abstract 26 Α lignan, identified 27 novel 4-(3,4-dihydroxyphenyl)-6,7-dimethoxy-3a,4-dihydronaphtho[2,3-c]furan-1(3H)-one, 28 named oleralignan A (1), together with six known compounds, loliolide (2), 29 30 isololiolide (3), dehydrololiolide (4), daphnetin (5), esculetin (6), and trans-coumaric acid methyl ester (7) was obtained from Portulaca oleracea L., while compounds 3, 4, 31 32 and 6-7 were isolated from the plant for the first time. Their structures were elucidated using spectroscopic methods, including one- and two-dimensional NMR and 33 high-resolution electrospray ionization time-of-flight mass spectrometry. In addition, 34 the results of activity assay demonstrated that compounds 1-7 have anticholinesterase 35 activities. 36 Keywords: Portulaca oleracea L.; lignan; isolation; anticholinesterase activity 37

as

38

39 **1. Introduction**

Portulaca oleracea L., an annual green herb, belonging to the family of Portulacaceae, 40 with branched and succulent stems, is edible and has a slightly acidic and salty taste 41 similar to spinach (Lim and Quah 2007). It is consumed as a vegetable and has been 42 reported to provide better nutrition than the major cultivated vegetables (Yazici et al. 43 2007). It is widely distributed in Africa, China, India, Australia, Middle East, Europe 44 and America (Rashed et al. 2003). It has been listed by the World Health Organization 45 as one of the most used medicinal plants and has been given the term 'Global 46 47 Panacea' (Zheng et al. 2017). As a traditional Chinese medicine, it is well-known as diuretic, febrifuge, antiseptic, antispasmodic and vermifuge (Shen et al. 2013). At the 48 same time, P. oleracea L. has been reported to possess a wide variety of 49 pharmacological effects, such as anti-inflammatory (Meng et al. 2016), antibacterial 50 (Nayaka et al. 2014), antiulcerogenic (Karimi et al. 2004), antitumor (Shen et al. 51 2013), antioxidant (Yang et al. 2019), antidiabetic (Bai et al. 2016), or 52 anticholinesterase (Xiu et al. 2019), among others. These activities have been related 53 to its chemical constituents including alkaloids (Zhao et al. 2019), flavonoids (Yang et 54 al. 2018), lignans (Ma et al. 2018), fatty acids (Teixeira et al. 2010), or minerals 55 56 (Uddin et al. 2012). In the present work, we isolated 7 intersting compounds from P. oleracea L. including 1 new arylnaphthalene lignan containing 2 methoxy groups. At 57 58 the same time, some lignans have been reported to have anticholinesterase activity, and the methoxy group in lignans can effectively enhance its anticholinesterase effect 59 60 (Salleh et al. 2016). However, study on the anticholinesterase activity of arylnaphthalene lignans has not been found. Therefore, we undertook to evaluate their 61 62 anticholinesterase activities following the modified Ellman's method.

63

64 **2. Results and discussion**

65 2.1. Structure elucidation

66 Compound **1**, a yellowish powder, has the molecular formula $C_{20}H_{18}O_6$, as deduced 67 from the HR-ESI-TOF-MS deprotonated molecular ion at m/z 353.1021 [M-H]⁻ 68 (calcd. for $C_{20}H_{17}O_6^-$, 353.1031), corresponding to 12 degrees of unsaturation. The 69 examination of the ¹H, ¹³C, and HSQC spectra of **1** demonstrated that several signals 70 were very broad in ¹H and ¹³C NMR spectra. Some signals were also duplicated. This 71 eventually turned out to originate from the slow rotation of the unsymmetrical phenyl ring (1'-6'). This phenyl ring appears in ¹H NMR in the form of a very broad signal between 6.70 and 6.94 ppm integrating for 3 protons. The signals of the methoxy group in C-6 ($\delta_{\rm H}$ 3.73, $\delta_{\rm C}$ 55.6) and the methine 3a ($\delta_{\rm H}$ 3.55, $\delta_{\rm C}$ 39.7) are also very broad due to the proximity of the rotating phenyl ring.





2





 $HO = \frac{5}{5} = \frac{7}{5} = \frac{0}{9} OCH_3$

7

77

76

78 Figure 1

79

With regard to the structural determination itself, it was possible to establish the 80 presence of a 1,2,4,5-tetrasubstituted benzene ring based on the signals of protons H-5 81 ($\delta_{\rm H}$ 6.16) and H-8 ($\delta_{\rm H}$ 7.16) together with their respective carbons at $\delta_{\rm C}$ 114.9 and 82 113.9 and their HMBC correlations with non-protonated carbons of the benzene ring 83 (Table S1 in supplementary material, Figure 2). Since protons H-5 and H-8 correlated 84 85 with both C-6 and C-7, the assignment of both methoxy groups was based on the COSY and ROESY correlations of MeO-C7 with H-8, but also the ROESY 86 correlation of MeO-C6 with H-2'. The COSY and ROESY spectra also provided key 87 information regarding the substituents in positions 4a and 8a. Thanks to these data, it 88

was possible to position H-4 close to H-5 and H-9 close to H-8. This was confirmed by the HMBC correlations of H-4 with C-4a and C-8a and of H-9 with C-4a, C-8a and C-8. The COSY spectrum defined a proton sequence H-4/H-3a/H-3, and the proton and carbon chemical shifts in position 3 ($\delta_{\rm H}$ 3.97/4.33, $\delta_{\rm C}$ 71.5) demonstrated that C-3 was link to an oxygen. The HMBC correlations H-9/C-3a, H-9/C-1, and H-3-y/C-1 completed the 3a,4-dihydroisobenzofuran-1-one subunit.





97 Figure 2

98

96

Additional correlations of H-4 with C-1', C-2' and C-6' demonstrated that an aromatic 99 ring was linked to C-4 and that both ortho positions were protonated. The fact that the 100 signals are very wide and are split does not prevent the structural determination 101 because protons H-2' and H-6' also correlated in ROESY with H-3a, H-4 and for H-2', 102 MeO-C6. As the lateral aromatic ring could not be symmetrical, two hydroxy groups 103 had to be positioned on the C-3' and C-4' carbons. The hydroxy protons are visible in 104 ¹H NMR at $\delta_{\rm H}$ 8.97 and 9.45. The remaining methine was assigned to position 5'. The 105 relative configuration of compound 1 was ascertained based on the 8.6 Hz coupling 106 107 between H-3a and H-4 along with the ROESY correlations H-4/H-3-x and H-3a/H-3-y which were consistent with an anti-periplanar configuration of protons H-3a and H-4. 108 Coupling constants of 8-10 Hz are found in analogous compounds described in the 109 literature, including conidendrin (Barton 1968; Davies and Jin 2003). Eventually, 110 compound 1 was identified as a conidendrin-related lignan and was given the trivial 111 name oleralignan A. 112

By comparison of the ¹H and ¹³C NMR spectral data with literature, the 6 known compounds (2-7) were identified, respectively, as loliolide (2) (Mori and Khlebnikov 1993), isololiolide (3) (Zheng et al. 2014), dehydrololiolide (4) (Zheng et al. 2014),

116 daphnetin (5) (Xu et al. 2008), esculetin (6) (Zhou et al. 2009), trans-coumaric acid

117 methyl ester (**7**) (Wan et al. 2012).

118 2.2. Anticholinesterase activity

Alzheimer's disease (AD) is the most common neurodegenerative disorder of aging, 119 accounting approximately for two-third of all cases of senile dementia (Tandon et al. 120 2000). AD is neurochemically characterised by a consistent deficit in cholinergic 121 neurotransmission, particularly affecting cholinergic neurons in the basal forebrain. 122 Symptoms of AD and other forms of dementia can be treated by the use of agents 123 124 which restore the level of acetylcholine through inhibition of both major cholinesterases: acetylcholinesterase and butyrylcholinesterase (Loizzo et al. 2009). 125 Studies have shown that some lignans exhibit neuroprotective effects, increasing 126 choline acetyltransferase activity, inhibiting acetylcholinesterase (AChE) activity in 127 vitro, and increasing hippocampal acetylcholine release in vivo (Howes and Houghton 128 2003). Consequently, the anticholinesterase activities of the 7 compounds were 129 evaluated using a microplate assay. Oleralignan A (1) inhibited enzyme activity at 130 58.31 \pm 0.23 μ M. Compounds 2-7 activity ranged from 71.50 \pm 0.39 μ M to 93.88 \pm 131 0.39 µM. Overall, oleralignan A exhibited higher anticholinesterase activity than 132 133 compounds 2-7(Table S2, in supplementary material).

134 **3. Experimental**

135 3.1. General experimental procedures

The NMR spectra were obtained using an AVANCE 600 MHz instrument (Bruker 136 Corporation, Switzerland). HRMS was determined using 6520 137 a quadrupole-time-of-flight mass spectrometer (Agilent, Palo Alto, CA). The UV data 138 was obtained from a HITACHI U-3010 spectrophotometer (Hitachi Ltd, Tokyo, 139 Japan), the IR spectrum and data obtained from IR200 spectrophotometer (Thermo 140 Electron Corporation, Waltham, MA). In the separation process, the GF₂₅₄ (Qingdao 141 Marine Chemical Co., Qingdao, China) was being as TLC filling, the silica gel 142 (100-200 and 200-300 mesh, Qingdao Marine Chemical Co., Qingdao, China), 143 polyamide resin (80-100 mesh, Taizhou Luqiao Sijia Biochemical Plastic Factory, 144 Zhejiang, China) and ODS (20-40 µm, GE Healthcare, Marlborough, MA) were used 145 as column chromatographic filling. The 96-well microplate reader (HBS-1096A) was 146 from Nanjing Detie Experimental Equipment Co., Ltd. (Nanjing, China). 147

148 *3.2. Plant materials and chemicals*

149 The whole herbs of *P. oleracea* L. were collected in Shijiazhuang (Hebei, China) in June 2017, and identified by Prof. Xixiang Ying. The voucher specimens (No. 150 20171001) were deposited at School of Pharmacy, Liaoning University of Traditional 151 Chinese Medicine. Acetylthiocholine iodide (ATCI) (purity \geq 99%) and AChE 152 (vitality ≥200 units/mg protein) were from Dalian Meilun Biotechnology Co., Ltd. 153 (Dalian, China), 5, 5-dithiobis-2-nitrobenzoic acid (DTNB) (purity \geq 99%) was from 154 Shanghai Jinsui Bio-Technology Co., Ltd. (Shanghai, China) and eserine (purity \geq 155 98%) was from Shanghai Hanxiang Biotechnology Co., Ltd. (Shanghai, China). The 156 157 HPLC grade formic acid, acetonitrile and methanol were purchased from Damao Chemical Reagent Plant (Tianjin, China, purity \geq 99.9%). All other reagents were 158 analytical grade reagents supplied by Jinfeng Chemical Factory (Tianjin, China), and 159 the purified water was from WAHAHA Company (Shenyang, China). 160

161 3.3. Isolation and identification

The dried whole herb of P. oleracea L. (250 kg) were extracted twice with 10 162 volumes of water for 2 hours each time, and then the water extract was concentrated 163 to obtain a crude extract (21 kg), which was subjected to a 100-200 mesh silica-gel 164 column chromatography (61×55 cm, approximately, 70 kg) with a 2 volumes of 165 166 ethyl acetate 3 times as the isocratic elution, affording the fraction evaporated (550 g). Then, the fraction was subjected to the 80-100 mesh polyamide resin column 167 168 chromatography (120×8 cm, approximately, 1 kg), eluting with water, 30%, 50%, 70% and 100% ethanol to obtain five fractions (4 L each). The fraction of 50% 169 170 extracting (121 g) was condensed then subjected to a 200-300 mesh silica-gel column $(120 \times 8 \text{ cm}, \text{ approximately}, 1 \text{ kg})$ for further purification with ethyl acetate, ethyl 171 172 acetate and methanol (5:1, 2:1, v/v) as the gradient eluant, obtaining three fractions (Frs. 1-3, 4 L each). The fraction of ethyl acetate (69 g) was subjected to the 20-40 µm 173 octadecylsilyl (ODS) column chromatography (25×3 cm, approximately, 150 g, 174 Ultimate XB-C18) with methanol and water (60:40, 70:30, 80:20, 90:10, 100:0, v/v) 175 as the gradient eluant under medium pressure, acquiring five fractions (A1-A5, 500 176 mL each). Among that, A1 was purified on a Sephadex LH-20 column (100 g, ϕ 2 × 177 150 cm) using methanol solvent to obtain seven fractions B1-B7, and then these 178 fractions were further prepared by UHPLC, using MeOH-0.1% formic acid as the 179 mobile phase, with flow rate of 1.0 mL/min, and obtained compound 1 (2 mg, purity 180 of > 98% with UHPLC, t_R 13.82 min, MeOH-0.1% formic acid, 61:39, v/v), 181

- compound 2 (2 mg, purity of > 98% with UHPLC, t_R 25.32 min, MeOH-0.1% formic 182 acid, 20:80, v/v), compound 3 (1 mg, purity of > 98% with UHPLC, t_R 18.14 min, 183 MeOH-0.1% formic acid, 20:80, v/v), compound 4 (3 mg, purity of > 97% with 184 UHPLC, t_R 17.67 min, MeOH-0.1% formic acid, 20:80, v/v), compound 5 (1 mg, 185 purity of > 98% with UHPLC, t_R 15.32 min, MeOH-0.1% formic acid, 12:88, v/v), 186 compound 6 (2 mg, purity of > 98% with UHPLC, t_R 19.14 min, MeOH-0.1% formic 187 acid, 10:90, v/v), compound 7 (3 mg, purity of > 98% with UHPLC, t_R 9.76 min, 188 MeOH-0.1% formic acid, 45:65, v/v). 189
- 190 Oleralignan A (1): Yellowish powder; UV (CH₃OH) λ max 348, 254 nm; IR (KBr) ν_{max} 191 2934, 2850, 1740, 1565, 1518, 1452, 1212 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆) and 192 ¹³C NMR (150 MHz, DMSO-*d*₆), see **Table S1** (in supplementary material); 193 HR-ESI-MS *m/z* 353.1021 [M-H]⁻ (calcd. for C₂₀H₁₇O₆⁻, 353.1031).

194 **3.4.** Anticholinesterase activity assay

- Acetylcholinesterase activities of compounds were assessed by a modified Ellman's 195 method (Ellman et al. 1961). In a 96-well plate, 140 μ L PBS (0.1 M, pH = 8.0, 196 containing 0.1 mol/L NaH₂PO₄ and Na₂HPO₄), 10 µL DTNB (15 mmol/L), 15 µL 197 AChE (0.2 U/mL) and 20 µL of sample solution serially diluted with methanol were 198 199 mixed and incubated at 37°C for 10 minutes, then 10 µL ATCI (15 mmol/L) was added and incubated at 20°C for 10 minutes. The absorbance was measured at 405 nm. 200 201 Eserine and methanol were used as positive and blank controls, respectively. The inhibition rate (%) of each sample AChE was calculated according to the following 202 203 formula (Aktumsek et al. 2013): Inhibition activity (%) = $[(A_{blank} - A_{sample})/A_{blank}] \times$ 100%, in which, A sample and A blank were respectively the absorbance of the test 204 compound and the blank control. The anticholinesterase activity was evaluated by the 205 value of IC₅₀ (means \pm SD, n = 3). 206

4. Conclusion

- In the study, a novel lignan named oleralignan A and six known compounds were isolated from the water extract of *P. oleracea* L. The results of anticholinesterase activities assay showed that oleralignan A presented a higher anticholinesterase activity than others, with IC₅₀ value of $58.31 \pm 0.23 \mu$ M.
- 212 Supplementary material
- Supporting information can be found in the online version of this article.
- 214 **Disclosure statement**

The authors have no conflicts of interest to disclose.

216 Acknowledgements

217 This work was supported by the National Natural Science Foundation of China (grant

218 number 82073990).

219 **References**

- 220 Aktumsek A, Zengin G, Guler GO, Cakmak YS, Duran A. 2013. Antioxidant
- potentials and anticholinesterase activities of methanolic and aqueous extracts of three
 endemic *Centaurea* L. species. Food Chem Toxicol. 55:290-296.
- Bai Y, Zang XL, Ma JS, Xu GY. 2016. Anti-diabetic effect of *Portulaca oleracea* L.
- polysaccharideandits mechanism in diabetic rats. Int J Mol Sci. 17(8):1201.
- 225 Barton GM. 1968. Preparation and structure of dimethyl- α -conidendrin-8-sulfonamide.
- 226 Can J Chem. 46(7):1164-1165.
- 227 Davies HML, Jin Q. 2003. Intermolecular C-H activation at benzylic positions:
- 228 synthesis of (+)-imperanene and (-)- α -conidendrin. Tetrahedron Asymmetr. 229 14(7):941-949.
- Ellman GL, Courtney KD, Jr VA, Featherstone RM. 1961. A new and rapid
 colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol.
 7(2):88-90.
- Howes MJR, Houghton PJ. 2003. Plants used in Chinese and Indian traditional
 medicine for improvement of memory and cognitive function. Pharmacol Biochem
 Be. 75(3):513-527.
- Karimi G, Hosseinzadeh H, Ettehad N. 2004. Evaluation of the gastric antiulcerogenic
 effects of *Portulaca oleracea* L. extracts in mice. Phytother Res. 18(6):484-487.
- Lim YY, Quah EPL. 2007. Antioxidant properties of different cultivars of *Portulaca oleracea*. Food Chem. 103(3):734-740.
- 240 Loizzo MR, Menichini F, Conforti F, Tundis R, Bonesi M, Saab AM, Statti GA,
- 241 Cindio Bd, Houghton PJ, Menichini F, et al. 2009. Chemical analysis, antioxidant,
- 242 antiinflammatory and anticholinesterase activities of Origanum ehrenbergii Boiss and
- 243 *Origanum syriacum* L. essential oils. Food Chem. 117(1):174-180.
- 244 Ma YF, Bao YR, Zhang WJ, Ying XX, Stien D. 2018. Four lignans from *Portulaca*
- oleracea L. and its antioxidant activities. Nat Prod Res. 34(16):2276-2282.
- 246 Meng YH, Ying ZM, Xiang Z, Hao D, Zhang WJ, Zheng Y, Gao YC, Ying XX.
- 247 2016. The anti-inflammation and pharmacokinetics of a novel alkaloid from

- 249 Mori K, Khlebnikov V. 1993. Carotenoids and degraded carotenoids, VIII: Synthesis
- of (+)-dihydroactinidiolide, (+)- and (-)-actinidiolide, (+)- and (-)-loliolide as well as
- 251 (+)- and (-)-epiloliolide. Liebigs Ann Chem. 1993:77-82.
- 252 Nayaka HB, Londonkar RL, Umesh MK, Tukappa A. 2014. Antibacterial attributes of
- apigenin, isolated from *Portulaca oleracea* L. Int J Bacteriol. 2014(2014):175851.
- Rashed AN, Afifi FU, Disib AM. 2003. Simple evaluation of the wound healing
- activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus
- musculus JVI-1. J Ethnopharmacol. 88(2-3):131-136.
- 257 Shen H, Tang G, Zeng G, Yang YJ, Cai XW, Li DL, Liu HC, Zhou NX. 2013.
- Purification and characterization of an antitumor polysaccharide from *Portulaca oleracea* L. Carbohyd Polym. 93(2):395-400.
- 260 Salleh WMNHW, Ahmad F, Yen KH, Zulkifli RM. 2016. Anticholinesterase and
- anti-inflammatory constituents from *Beilschmiedia pulverulenta* kosterm. Nat Pro Sci.
 22(4):225-230.
- 263 Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. 2000. Molecular genetics of
- 264 alzheimer's disease: the role of β -amyloid and the presenilins. Curr Opin Neurol. 265 13(4):377-384.
- Teixeira MC, Carvalho IS, Brodelius M. 2010. Omega-3 fatty acid desaturase genes isolated from purslane (*Portulaca oleracea* L.): expression in different tissues and
- response to cold and wound stress. J Agric Food Chem. 58(3):1870-1877.
- Uddin MK, Juraimi AS, Ali ME, Ismail MR. 2012. Evaluation of antioxidant
 properties and mineral composition of purslane (*Portulaca oleracea* L.) at different
 growth stages. Int J Mol Sci. 13(8):10257-10267.
- Wan C, Yuan T, Cirello AL, Seeram NP. 2012. Antioxidant and alpha-glucosidase
 inhibitory phenolics isolated from highbush blueberry flowers. Food Chem.
 135(3):1929-1937.
- Xiu F, Li XT, Zhang WJ, He F, Ying XX, Stien D. 2019. A new alkaloid from *Portulaca oleracea* L. and its antiacetylcholinesterase activity. Nat Prod Res.
 33(18):2583-2590.
- 278 Xu WZ, Jin HZ, Zhang WD, Fu JJ, Hu XJ, Zhang W, Yan SK, Shen YH. 2008.
- Studies on the chemical constituents of *Daphne pedunculata*. Chem Nat Compd.
 44(6):771-772.

²⁴⁸ *Portulaca oleracea* L. J Pharm Pharmacol. 68(3):397-405.

- 281 Yang X, Ying ZM, Liu HR, Ying XX, Yang GL. 2019. A new homoisoflavone from
- 282 *Portulaca oleracea* L. and its antioxidant activity. Nat Prod Res. 33(24):3500-3506.
- Yang X, Zhang WJ, Ying XX, Stien D. 2018. New flavonoids from *Portulaca oleracea* L. and their activities. Fitoterapia. 127:257-262.
- 285 Yazici I, Türkan I, Sekmen AH, Demiral T. 2007. Salinity tolerance of purslane
- 286 (Portulaca oleracea L.) is achieved by enhanced antioxidative system, lower level of
- lipid peroxidation and proline accumulation. Environ Exp Bot. 61(1):49-57.
- 288 Zhao CC, Zhang CG, He F, Zhang WJ, Leng AJ, Ying XX. 2019. Two new alkaloids
- from *Portulaca oleracea* L. and their bioactivities. Fitoterapia. 136:104166.
- 290 Zheng GY, Peng H, Li M, Gu W, Chen Z, Ling CQ. 2017. Antihepatocarcinoma
- 291 effect of *Portulaca oleracea* L. in mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB
- pathway. Evid Based Compl Alt. 2017(1):1-11.
- 293 Zheng JX, Zheng Y, Zhi H, Dai Y, Wang NL, Fang YX, Du ZY, Zhang K, Wu LY,
- Fan M. 2014. γ-lactone derivatives and terpenoids from selaginella uncinata and their
- protective effect against anoxia. Chem Nat Compd. 50(1):366-369.
- 296 Zhou HY, Hong JL, Shu P, Ni YJ, Qin MJ. 2009. A new dicoumarin and 297 anticoagulant activity from *Viola yedoensis* Makino. Fitoterapia. 80(5):283-285.